Assembly Biosciences
ASMB
75 hedge funds and large institutions have $376M invested in Assembly Biosciences in 2026 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 17 reducing their positions, and 10 closing their positions.
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
65% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 17
9% more funds holding
Funds holding: 69 → 75 (+6)
1.23% less ownership
Funds ownership: 86.77% → 85.54% (-1.2%)
19% less capital invested
Capital invested by funds: $467M → $376M (-$90.3M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$4.62M |
| 2 |
Millennium Management
New York
|
+$3.86M |
| 3 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$2.13M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.89M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$979K |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.32M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$7.16M |
| 3 |
EP
Eversept Partners
New York
|
-$3.39M |
| 4 |
SCM
Superstring Capital Management
New York
|
-$2.22M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.35M |
ASMB Hedge Fund Activity: Q1 2026 in Review
75 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q1 2026, worth a combined $376M — down 19% from $467M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ASMB positions and 10 closed out — a net gain of 7 holders — while 28 added to existing stakes and 17 trimmed.
The largest buyer was Parkman Healthcare Partners, adding an estimated $4.62M. The largest seller was Point72 Asset Management, cutting an estimated $7.32M.
- 75 institutional investors held Assembly Biosciences (ASMB) as of Q1 2026, up from 69 in Q4 2025.
- Funds reported $376M of Assembly Biosciences stock for Q1 2026, down 19% quarter-over-quarter.
- 17 funds opened new Assembly Biosciences positions in Q1 2026 and 10 closed out, a net change of +7 holders.
- The largest Assembly Biosciences buyer in Q1 2026 was Parkman Healthcare Partners, an estimated $4.62M added.
- The largest Assembly Biosciences seller in Q1 2026 was Point72 Asset Management, an estimated $7.32M sold.
Based on aggregated 13F filings for Q1 2026.